Pramod K Srivastava

List of Publications by Year
in descending order

42 papers	6,560 citations	257101 24 h-index	288905 40 g-index
42 all docs	42 docs citations	42 times ranked	6693 citing authors

#	Article	IF	Citations
1	An unbiased approach to defining bona fide cancer neoepitopes that elicit immune-mediated cancer rejection. Journal of Clinical Investigation, 2021, 131, .	3.9	22
2	Reversion analysis reveals the in vivo immunogenicity of a poorly MHC I-binding cancer neoepitope. Nature Communications, 2021, 12, 6423.	5.8	18
3	Cross-dressing of CD8Î±+ Dendritic Cells with Antigens from Live Mouse Tumor Cells Is a Major Mechanism of Cross-priming. Cancer Immunology Research, 2020, 8, 1287-1299.	1.6	25
4	Sympathetic nervous tone limits the development of myeloid-derived suppressor cells. Science Immunology, 2020, 5, .	5.6	13
5	Prediction of cancer neoepitopes needs new rules. Seminars in Immunology, 2020, 47, 101387.	2.7	19
6	Low-Level Inhibition of Hsp90 Forces Cells to Tip Their (Antigenic) Hand. Clinical Cancer Research, 2019, 25, 6277-6279.	3.2	1
7	Mass spectrometryâ€"driven exploration reveals nuances of neoepitope-driven tumor rejection. JCI Insight, 2019, 4, .	2.3	42
8	CD11c+ MHCIIlo GM-CSF-bone marrow-derived dendritic cells act as antigen donor cells and as antigen presenting cells in neoepitope-elicited tumor immunity against a mouse fibrosarcoma. Cancer Immunology, Immunotherapy, 2018, 67, 1449-1459.	2.0	12
9	Endocannabinoid system acts as a regulator of immune homeostasis in the gut. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 5005-5010.	3.3	136
10	Tumor Control Index as a new tool to assess tumor growth in experimental animals. Journal of Immunological Methods, 2017, 445, 71-76.	0.6	20
11	Neoepitopes as cancer immunotherapy targets: key challenges and opportunities. Immunotherapy, 2017, 9, 361-371.	1.0	58
12	George Klein (1925â€"2016) A Prescient, Luminous Voice. Cancer Immunology Research, 2017, 5, 272-272.	1.6	1
13	Consensus nomenclature for CD8⁺T cell phenotypes in cancer. OncoImmunology, 2015, 4, e998538.	2.1	119
14	Smoking-induced immune deviation contributes to progression of bladder and other cancers. OncoImmunology, 2015, 4, e1019199.	2.1	6
15	Neoepitopes of Cancers: Looking Back, Looking Ahead. Cancer Immunology Research, 2015, 3, 969-977.	1.6	59
16	Classification of current anticancer immunotherapies. Oncotarget, 2014, 5, 12472-12508.	0.8	395
17	Genomic and bioinformatic profiling of mutational neoepitopes reveals new rules to predict anticancer immunogenicity. Journal of Experimental Medicine, 2014, 211, 2231-2248.	4.2	324
18	Harnessing the antigenic fingerprint of each individual cancer for immunotherapy of human cancer: genomics shows a new way and its challenges. Cancer Immunology, Immunotherapy, 2013, 62, 967-974.	2.0	24

#	Article	IF	Citations
19	Immune response to mutant neo-antigens. OncoImmunology, 2013, 2, e26382.	2.1	9
20	Dendritic cells sequester antigenic epitopes for prolonged periods in the absence of antigen-encoding genetic information. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 17543-17548.	3.3	14
21	Towards accurate detection and genotyping of expressed variants from whole transcriptome sequencing data. BMC Genomics, 2012, 13, S6.	1.2	38
22	Area under the curve as a tool to measure kinetics of tumor growth in experimental animals. Journal of Immunological Methods, 2012, 382, 224-228.	0.6	47
23	An open invitation to the cancer immunology community. Cancer Immunity, 2012, 12, 1.	3.2	0
24	Identification of chaperones as essential components of the tumor rejection moieties of cancers. Cancer Immunity, 2012, 12, 5.	3.2	1
25	Treating human cancers with heat shock protein-peptide complexes: the road ahead. Expert Opinion on Biological Therapy, 2009, 9, 179-186.	1.4	35
26	New Jobs for Ancient Chaperones. Scientific American, 2008, 299, 50-55.	1.0	23
27	An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised phase III trial. Lancet, The, 2008, 372, 145-154.	6.3	312
28	Phase III Comparison of Vitespen, an Autologous Tumor-Derived Heat Shock Protein gp96 Peptide Complex Vaccine, With Physician's Choice of Treatment for Stage IV Melanoma: The C-100-21 Study Group. Journal of Clinical Oncology, 2008, 26, 955-962.	0.8	238
29	Heat-shock protein 90 associates with N-terminal extended peptides and is required for direct and indirect antigen presentation. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 1662-1667.	3.3	93
30	Quantitative Analysis of Cellular Antigen and Determination of the Halfâ€Life of Hsp90â€peptide complexes in vivo. FASEB Journal, 2008, 22, 1067.15.	0.2	0
31	Therapeutic cancer vaccines. Current Opinion in Immunology, 2006, 18, 201-205.	2.4	132
32	Immunotherapy for human cancer using heat shock protein-peptide complexes. Current Oncology Reports, 2005, 7, 104-108.	1.8	101
33	Hypothesis: controlled necrosis as a tool for immunotherapy of human cancer. Cancer Immunity, 2003, 3, 4.	3.2	19
34	INTERACTION OFHEATSHOCKPROTEINS WITHPEPTIDES ANDANTIGENPRESENTINGCELLS: Chaperoning of the Innate and Adaptive Immune Responses. Annual Review of Immunology, 2002, 20, 395-425.	9.5	802
35	Roles of heat-shock proteins in innate and adaptive immunity. Nature Reviews Immunology, 2002, 2, 185-194.	10.6	965
36	Immunization of cancer patients with autologous cancer-derived heat shock protein gp96 preparations: A pilot study. International Journal of Cancer, 2000, 88, 232-238.	2.3	231

#	Article	IF	Citations
37	CD91: a receptor for heat shock protein gp96. Nature Immunology, 2000, 1, 151-155.	7.0	646
38	Immunotherapy of human cancer: lessons from mice. Nature Immunology, 2000, 1, 363-366.	7.0	135
39	Heat Shock Proteinâ€"Peptide Complexes, Reconstituted In Vitro, Elicit Peptide-specific Cytotoxic T Lymphocyte Response and Tumor Immunity. Journal of Experimental Medicine, 1997, 186, 1315-1322.	4.2	526
40	Immunotherapy of Tumors with Autologous Tumor-Derived Heat Shock Protein Preparations. Science, 1997, 278, 117-120.	6.0	646
41	Peptide-Binding Heat Shock Proteins in the Endoplasmic Reticulum: Role in Immune Response to Cancer and in Antigen Presentation. Advances in Cancer Research, 1993, 62, 153-177.	1.9	149
42	Individually distinct transplantation antigens of chemically induced mouse tumors. Trends in Immunology, 1988, 9, 78-83.	7.5	104